Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Muscle atrophy-also known as muscle wasting-is a debilitating syndrome that slowly develops with age (sarcopenia) or rapidly appears at the late stages of deadly diseases such as cancer, AIDS, and sepsis (cachexia). Despite the prevalence and the drastic detrimental effects of these two syndromes, there are currently no widely used, effective treatment options for those suffering from muscle wasting. In an attempt to identify potential therapeutic targets, the molecular mechanisms of sarcopenia and cachexia have begun to be elucidated. Growing evidence suggests that inflammatory cytokines may play an important role in the pathology of both syndromes. As one of the key cytokines involved in both sarcopenic and cachectic muscle wasting, tumor necrosis factor α (TNFα) and its downstream effectors provide an enticing target for pharmacological intervention. However, to date, no drugs targeting the TNFα signaling pathway have been successful as a remedial option for the treatment of muscle wasting. Thus, there is a need to identify new effectors in this important pathway that might prove to be more efficacious targets. Inducible nitric oxide synthase (iNOS) has recently been shown to be an important mediator of TNFα-induced cachectic muscle loss, and studies suggest that it may also play a role in sarcopenia. In addition, investigations into the mechanism of iNOS-mediated muscle loss have begun to reveal potential therapeutic strategies. In this review, we will highlight the potential for targeting the iNOS/NO pathway in the treatment of muscle loss and discuss its functional relevance in sarcopenia and cachexia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“individuals over the age of 64 suffer from sarcopenia, and that percentage is doubled in individuals over the age of 80 [17, 18].”
BackgroundMissing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 1×
“TNFα is known to mediate its effects through the transcription factor NF-κB, which is responsible for the regulation of a wide variety of genes [70].”
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 1×
“In some patients, cachexia may lead to the onset of sarcopenia, inducing a state known as cachexia-related sarcopenia [1, 3].”
BackgroundSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 2×
“the phenomenon whereby aging individuals would exhibit a gradual loss of muscle mass [15].”
BackgroundFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087
IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
Luedde, T., & Schwabe, R. F. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.213 · Cited by 1,345
Visser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., Nevitt, M., & Harris, T. B. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m326 · Cited by 1,294
Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women
Iannuzzi-Sucich, M., Prestwood, K. M., & Kenny, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.12.m772 · Cited by 890 · cited 1×
“individuals over the age of 64 suffer from sarcopenia, and that percentage is doubled in individuals over the age of 80 [17, 18].”
Background
Cited by
Molecular and cellular mechanisms of skeletal muscle atrophy: an update
Fanzani, A., Conraads, V. M., Penna, F., & Martinet, W. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0074-6 · Cited by 370
Sarcopenia: Molecular Pathways and Potential Targets for Intervention
Pascual-Fernández, J., Fernández-Montero, A., Córdova-Martínez, A., Pastor, D., Martínez-Rodríguez, A., & Roche, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228844 · Cited by 125
“Inhibitors of iNOS activity have demonstrated a clear efficiency to prevent symptoms of muscle wasting [81].”
BackgroundHall, D. T., Griss, T., Ma, J. F., Sanchez, B. J., Sadek, J., Tremblay, A. M. K., Mubaid, S., Omer, A., Ford, R. J., Bedard, N., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708307 · Cited by 88
“Extended cytokine exposure results in the continued activation of inflammatory signaling within muscle cells, leading to the expression of pro-cachectic genes (Guttridge et al, 2000; Bonetto et al, 2011; Hall et al, 2011; Fearon et al, 2012; Bonaldo & Sandri, 2013).”
BackgroundSelf-citationPalomero, J., Vasilaki, A., Pye, D., McArdle, A., & Jackson, M. J. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00530.2012 · Cited by 71
“Changes in nitric oxide synthases (NOS) have been reported during aging with a decreased expression of neuronal NOS and an increase in inducible NOS expression both described (16, 49).”
BackgroundBlot, S. (2021) · Intensive Care Medicine · doi:10.1007/s00134-020-06276-z · Cited by 73
Master Regulators of Muscle Atrophy: Role of Costamere Components
Gorza, L., Sorge, M., Seclì, L., & Brancaccio, M. (2021) · Cells · doi:10.3390/cells10010061 · Cited by 31
Metadata
- Authors
- Hall, D. T., Ma, J. F., Di Marco, S., & Gallouzi, I.-E.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2011-08-07
- Volume
- 3
- Issue
- 8
- Pages
- 702-715
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2122370348
- Cited by
- 95
- References
- 26
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.